Current research approaches to the Warburg effect focus on depriving cancer cells of nutrients on the one hand and oxidative stress on the other, which makes other therapies more effective. The biotech company Vidac Pharma is fully committed to reversing the Warburg effect and focuses primarily on active ingredients for skin and liver cancer. In particular, VDA-1275, a drug candidate for solid tumors, has recently caused a stir: Preclinical studies have shown that VDA-1275 can increase the efficacy of chemotherapeutic agents against liver cancer by a factor of 1000.
News & Events